# lung adenocarcinoma (LUAD) - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 4
- Task type: PROGNOSIS
- Tissue / sample source: lung adenocarcinoma tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: a2c9355177479f23c6c81afe1b39ba697ac131cc344bb83120b98e2c6bbfee49
- Response HTTP status: 200
- Prompt tokens: 37157
- Completion tokens: 21422
- Reasoning tokens: 4016
- Total tokens: 58579
- API requests reported: 3
- Elapsed seconds: 74.868
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 957.651
- Question handoff seconds: 970.897
- Final benchmark system: E2seq; file rank 2/5; original repeat 4; model vendor: MiniMax

---
<think>The user wants a comprehensive multidimensional interpretation of prognostic transcriptomic data for lung adenocarcinoma (LUAD). Let me carefully analyze the data and evidence provided.

**Critical Data Quality Observations:**

1. **Extreme hazard ratios**: Many genes have HR values of 5.18e+21, which is astronomically high and not biologically plausible. These are clearly artifacts of:
   - Possibly sparse expression data (many zeros)
   - Likely Y-chromosome or testis-specific genes (RBMY1F, FAM9A, TCP10L3, TEX13A, USP9YP3, CDY10P, RBMY2AP, TTTY4C) - these shouldn't be prognostic in female-predominant LUAD cohort
   - Pseudogenes and lncRNAs with near-zero expression in tumor
   
2. **Sex chromosome artifacts**: The top "risk-associated" genes include many Y-chromosome/testis-specific genes (RBMY1F, FAM9A, RBMY2AP, TTTY4C, TEX13A, USP9YP3, CDY10P, VENTXP7, TCP10L3) which suggests **sex-based confounding** in the cohort.

3. **Pseudogenes and unprocessed pseudogenes**: Many "genes" are pseudogenes (ATP5PBP2, RAP1BP2, HMGN2P39, MTND1P1, ETFRF1P1, ATG4AP1, AMMECR1LP1, DNM1P49, DIMT1P1, RBMXP1, CMAHP) - these are likely artifacts of read mapping.

4. **lncRNAs with no clear function**: Many RP11-* and CTD-* lncRNAs without characterization.

5. **Direction conflict noted for Y_RNA**: 163 rows in conflict - this is a strong data quality flag.

6. **Reasonable HRs in some genes**: PITX3 (HR=1.43), DKK1 (HR=1.48), TLE1 (HR=1.48), LDLRAD3 (HR=1.42), KRT6A (HR=1.39), FUT4 (HR=1.40), RHOF (HR=1.40) - these have plausible biological effects.

7. **Protective genes**: RBMXP1 (HR=0.21), TCP10L3 (HR=1.93e-22, direction conflict - this is classified as protective but with extreme magnitude), CRNDE (HR=0.72), CMAHP (HR=0.71).

8. **GO/KEGG batch before RAG**: 
   - GO: Regulation of Wnt signaling pathway
   - Planar cell polarity pathway
   - Cell junction disassembly
   - KEGG: Wnt signaling, Mannose type O-glycan biosynthesis, Glycosphingolipid biosynthesis

**Pathway and Network Evidence:**

- DKK1 is a well-known Wnt antagonist
- TLE1 is a Wnt/β-catenin pathway component (Groucho/TLE family)
- LDLRAD3 is related to Wnt
- KRT6A - keratin
- FUT4 - fucosyltransferase (glycosylation)
- RHOF - Rho GTPase, actin
- RGS20 - G protein signaling
- CRNDE - lncRNA, has been linked to various cancers
- CMAHP - pseudogene related to CMAH gene
- ITGB1-DT - lncRNA near ITGB1
- CREG2 - cellular repressor of E1A-stimulated genes
- PITX3 - transcription factor
- VAX1 - transcription factor
- LINC01312, LINC02178, LINC01910, LINC02323, LINC02802, LINC00707 - uncharacterized lncRNAs

**Literature evidence:**
- ITGB1-DT has been proposed as a biomarker in LUAD (PMID 34906142)
- RhoF high expression predicts worse survival (PMID 34405015) - but in AML
- Ferritinophagy genes associated with NSCLC prognosis (PMID 40124684)

**Data Quality Warning:**
The dataset is highly degenerate with extreme HRs suggesting:
1. Sex chromosome genes dominating (Y-linked genes should not be prognostic in predominantly female LUAD)
2. Many pseudogenes being mis-mapped
3. Direction conflict in 163 rows for Y_RNA
4. P=0 values are not statistically valid - these are numerical underflow artifacts

**Most Biologically Plausible Core Genes (with reasonable HRs and statistical values):**
1. DKK1 (HR=1.48, P=4.27e-10) - Wnt antagonist
2. TLE1 (HR=1.48, P=3.2e-8) - Wnt pathway
3. PITX3 (HR=1.43, P=4.14e-14) - transcription factor
4. KRT6A (HR=1.39, P=4.22e-7) - keratin
5. FUT4 (HR=1.40, P=4.55e-7) - glycosylation
6. RHOF (HR=1.40, P=6.31e-7) - Rho GTPase
7. LDLRAD3 (HR=1.42, P=3.34e-7) - Wnt-related
8. RGS20 (HR=1.35, P=9.55e-7) - G protein signaling
9. CRNDE (HR=0.72, protective) - lncRNA
10. CMAHP (HR=0.71, protective) - pseudogene

**Core Biological Programs:**

1. **Wnt signaling dysregulation (Risk)**: DKK1, TLE1, LDLRAD3 - the strongest coherent biological signal
2. **Epithelial/keratin differentiation (Risk)**: KRT6A
3. **Glycosylation remodeling (Risk)**: FUT4
4. **Small GTPase signaling/cytoskeleton (Risk)**: RHOF, RGS20
5. **Long non-coding RNAs (mixed)**: CRNDE protective, LINC01312/LINC02178 etc. risk

**Limitations to emphasize:**
- Sex chromosome/pseudogene artifacts
- Extreme HRs reflect sparse data, not biological signal
- No independent cohort validation
- Direction conflict in 163 rows for Y_RNA
- Many HRs of 5e21 are physically impossible for survival analysis

Let me structure my response now.</think>

# Multidimensional Interpretation of an LUAD Prognostic Transcriptomic Signature

## 0. Data-quality warning (read this first)

The uploaded survival statistics are **degenerate** in several ways, and any program-level interpretation must be framed against them:

- **Implausible HR magnitudes.** A large fraction of the 100 selected genes carry HRs on the order of 10⁹–10²¹ (e.g., 52 rows with HR ≈ 5.18 × 10²¹; further rows at 10⁵–10¹⁶). A hazard ratio above ~10⁴–10⁵ is effectively meaningless in a Cox model over human lifetimes and reflects numerical underflow or near-zero event-time variance, not biology.
- **P = 0 / FDR = 0 for 70/100 rows.** These are not valid significance values; they indicate either complete separation or computational underflow on sparse expression columns.
- **Sex-chromosome / testis-restricted genes dominate the top of the list.** RBMY1F, FAM9A, RBMY2AP, TTTY4C, TEX13A, USP9YP3, CDY10P, VENTXP7, TCP10L3 are all Y-linked and testis-/germline-restricted. They should not be prognostic in LUAD tumor tissue unless the cohort is overwhelmingly male and Y-expression is a proxy for male sex.
- **Pseudogene and unassigned-RNA clutter.** HMGN2P39, ATP5PBP2, RAP1BP2, RNY1P3, MTND1P1, ETFRF1P1, ATG4AP1, AMMECR1LP1, DRAXINP1, DIMT1P49, DNM1P49, RBMXP1, CMAHP are processed/unprocessed pseudogenes or unassigned RNAs; the same applies to the 12 `UNMAPPED_ENSEMBL_*` rows. They are likely read-mapping artifacts.
- **Internal direction conflict.** `Y_RNA` carries 163 ledger rows with mixed direction — the 100-row table here has HR ≈ 5.18 × 10²¹ as a single deterministic representative, but the full ledger disagrees about its direction. This is a flag for QC issues, not a usable signal.
- **No independent cohort was supplied.** External replication status = `not_available`. Pathway recurrence, source coverage, and literature record counts are **not** replication.

These features mean that **direct statistical evidence in this dataset should be trusted primarily for the small subset of genes with biologically reasonable HRs (≈0.7–1.5) and finite P values.** All "biological programs" below are presented with this caveat explicitly attached; downstream sections label which parts are *established evidence* in the strict sense, which are *supported hypotheses*, and which are *exploratory*.

---

## 1. Overall biological interpretation

After excluding the sex-linked, pseudogene, and extreme-HR rows, the cohort reduces to ~30 plausibly behaved prognostic features. The dominant theme is **Wnt-pathway dysregulation together with epithelial-keratin and glycosylation remodeling** as risk-associated programs, plus a small set of long non-coding RNAs whose directions are consistent across rows (e.g., CRNDE protective). The GO/KEGG batch run prior to synthesis independently retrieved *Regulation of Wnt signaling pathway*, *Planar cell polarity pathway*, *Cell junction disassembly*, and *Mannose-type O-glycan biosynthesis / glycosphingolipid biosynthesis / Wnt signaling*, which converge on the same biology and reinforce the Wnt + glycosylation + cell-junction axis.

The smaller subset with HR < 1 (RBMXP1, TCP10L3, CRNDE, CMAHP) is heterogeneous: TCP10L3 is Y-linked and almost certainly a sex-correlated artifact; RBMXP1 and CMAHP are pseudogenes with weak plausibility as protective factors in tumor epithelium; CRNDE is the only biologically credible protective candidate.

**Net interpretation:** what survives the QC filter is a small, internally coherent signature — Wnt signaling (DKK1, TLE1, LDLRAD3), epithelial/squamous-like keratin expression (KRT6A), fucosyltransferase-driven glycosylation (FUT4), and Rho-family GTPase signaling (RHOF, RGS20) — flagged as adverse prognostic features, with CRNDE as the lone consistently protective lncRNA candidate.

---

## 2. Core biological programs

I list five programs, ordered by independence and coherence, not by HR magnitude.

### Program 1 — Wnt signaling dysregulation (Risk-associated)
- **Supporting genes with reliable statistics:** DKK1 (HR=1.475, FDR=3.5e-7), TLE1 (HR=1.484, FDR=2.5e-5), LDLRAD3 (HR=1.420, FDR=2.2e-4).
- **Standard pathway:** GO:0030111 *Regulation of Wnt signaling pathway*; KEGG `Wnt signaling pathway` (also retrieved by the pre-RAG GO/KEGG batch).
- **Why these genes collectively:** DKK1 is a canonical secreted Wnt antagonist (LRP5/6 decoy); TLE1/Groucho is a TCF/LEF co-repressor that biases β-catenin output toward repression; LDLRAD3 modulates LDLR-related Wnt-receptor turnover. Three different nodes of the Wnt axis moving in the same direction (risk) is a coherent program-level signal.
- **Strength of evidence:** Moderate — three independent nodes, pathway ontology recurrence, prior LUAD Wnt literature. **Limitation:** not biologically redundant with one another, but the magnitudes are modest (HRs 1.4–1.5); no independent cohort was run.

### Program 2 — Glycosylation and cell-surface glycan remodeling (Risk-associated)
- **Supporting genes:** FUT4 (HR=1.403, FDR=2.9e-4). PITX3 (HR=1.429, FDR=3.5e-11) is a transcription factor with documented upstream links to fucosylation programs in some contexts but is not itself a glycosyltransferase.
- **Standard pathway:** KEGG *Mannose type O-glycan biosynthesis*, *Glycosphingolipid biosynthesis* (retrieved in the GO/KEGG batch). GO:0150146 *Cell junction disassembly*.
- **Why:** FUT4 (α1,3-fucosyltransferase, Lewis-y synthesis) has been associated with epithelial-mesenchymal transition and aggressive phenotypes in several carcinomas. The KEGG recurrence in glycan biosynthesis pathways supports the same direction.
- **Strength of evidence:** Weak-to-moderate — single gene (FUT4) with strong statistical support and prior oncology literature; PITX3 inclusion is tentative. **Limitation:** only one core enzyme of the pathway; program is named mostly from ontology retrieval, not from gene-set enrichment on the uploaded data.

### Program 3 — Squamous-like epithelial / cytoskeletal re-programming (Risk-associated)
- **Supporting genes:** KRT6A (HR=1.390, FDR=2.8e-4). Network context also pulls in RHOF (HR=1.403, FDR=4.0e-4) as a cytoskeletal modulator.
- **Standard pathway:** Reactome/QuickGO MF:*protein binding*; BP:*actin filament organization*, *regulation of small GTPase mediated signal transduction* (RHOF).
- **Why:** KRT6A is a keratin expressed in squamous and basal-type epithelia; in LUAD, high KRT6A often co-occurs with squamous-mixed histology and worse outcomes. RHOF (Rho family GTPase) is consistent with cytoskeletal re-organization.
- **Strength of evidence:** Moderate. **Limitation:** KRT6A is a single gene; histology confounding (LUAD with squamous features) cannot be ruled out without slide-level annotation.

### Program 4 — G-protein / Rho-family signaling (Risk-associated)
- **Supporting genes:** RGS20 (HR=1.352, FDR=5.8e-4), RHOF (HR=1.403, FDR=4.0e-4).
- **Standard pathway:** Reactome *G alpha (i) signalling events*, *G alpha (z) signalling events* (RGS20); GO MF *GTPase activity*, *guanyl-nucleotide exchange factor activity* (RHOF).
- **Why:** RGS20 is a GTPase-activating protein for Gαi/Gαz (high STRING confidence for GNAZ 0.95, GNB5 0.95, GNAI2 0.82, GNAQ 0.80 — direct physical interactions). RHOF is a Rho GTPase involved in actin dynamics. Two GTPase-axis genes moving in the same direction.
- **Strength of evidence:** Moderate — direct STRING interaction evidence is unusually strong here (RGS20 is one of the few proteins in the cohort with documented physical interactors at confidence ≥0.8). **Limitation:** still only two genes, and no direct physical link between RGS20 and RHOF — these are *parallel* axes within the same broader signaling module.

### Program 5 — Long non-coding RNA axis with mixed direction (Risk- and protective-associated)
- **Supporting genes:** CRNDE (HR=0.716, FDR=1.0e-4, protective) and several uncharacterized lincRNAs with HRs 1.17–1.37 (LINC01312, LINC02178, LINC01910, LINC02323, LINC02802, LINC00707, RP11-1057N3.2, RP11-96B2.1, RP11-438B23.2, RP11-58O9.2, ITGB1-DT, etc.).
- **Standard pathway:** No coherent ontology term.
- **Why:** ITGB1-DT has prior literature specifically in LUAD (PMID 34906142 reports an ITGB1-DT/ARNTL2 axis with prognostic relevance); CRNDE is a well-known cancer lncRNA but reported as oncogenic in many contexts — its protective HR here is interesting but **contradicts** the broader literature and is therefore a *direction-conflict* hypothesis worth testing, not asserting.
- **Strength of evidence:** Weak. **Limitation:** the protective direction of CRNDE conflicts with prior literature and may be context-dependent or an artifact of the cohort; uncharacterized lincRNAs without external functional annotation cannot be elevated to "programs."

---

## 3. Key genes and interaction modules

The ten candidates below are filtered to those with biologically credible statistics (HR 0.7–1.5, finite P, ontology-relevant). Each entry distinguishes *direct physical interaction*, *regulatory*, *co-expression*, *pathway co-membership*, and *indirect/putative* relationships.

1. **DKK1 (HR=1.475, FDR=3.5e-7; Risk)** — Canonical Wnt antagonist. Pathway co-membership with the Wnt program (Program 1); no STRING physical interaction documented in the retrieved evidence pack. Established prognostic biomarker candidate in multiple carcinomas.
2. **TLE1 (HR=1.484, FDR=2.5e-5; Risk)** — Groucho/TLE co-repressor of TCF/LEF. Pathway co-membership with the Wnt program; STRING evidence for interaction with ASXL2 (single STRING partner retrieved). Direct protein-protein interaction evidence with ASXL2 (not with other Wnt components).
3. **LDLRAD3 (HR=1.420, FDR=2.2e-4; Risk)** — LDLR-family receptor, modulates Wnt receptor turnover. Pathway co-membership with Wnt program. STRING interaction with APP retrieved.
4. **FUT4 (HR=1.403, FDR=2.9e-4; Risk)** — α1,3-fucosyltransferase. STRING partners B3GNT3, B4GALT1 retrieved — both glycosyltransferases, indicating **direct physical interaction** within a glycosyltransferase complex. Co-membership with KEGG mannose-type O-glycan biosynthesis / glycosphingolipid biosynthesis.
5. **KRT6A (HR=1.390, FDR=2.8e-4; Risk)** — Keratin. MF:*protein binding*; potential **co-expression** (not direct interaction) with other keratins and epithelial markers. Literature evidence (PMID 42216026) suggests mesenchymal-stem-cell-derived KRT6A as biomarker in alopecia; oncology relevance is via squamous-like histology, not direct mechanism.
6. **RHOF (HR=1.403, FDR=4.0e-4; Risk)** — Rho GTPase. STRING partners ACTN1, ARHGAP1 retrieved (cytoskeletal linkers); these are **direct physical interactions** at moderate-to-high STRING confidence. Prior literature (PMID 34405015) implicates high RhoF in worse survival in AML — independent-cancer, *not* LUAD replication.
7. **RGS20 (HR=1.352, FDR=5.8e-4; Risk)** — RGS GAP for Gαi/Gαz. STRING interactions: GNAZ (0.95), GNB5 (0.95), SUCLG2 (0.85), GNAI2 (0.82), GNAQ (0.80) — these are **direct physical interactions**, the strongest interaction evidence in the entire cohort. Reactome membership: Gα(i) and Gα(z) signalling events.
8. **PITX3 (HR=1.429, FDR=3.5e-11; Risk)** — Paired-like homeodomain transcription factor. Strongest finite P-value in the reliable subset, yet no retrieved STRING, Reactome, or TRRUST interactors in the evidence pack — relationship to other selected genes is currently *putative / pathway co-membership only*.
9. **CRNDE (HR=0.716, FDR=1.0e-4; Protective)** — lncRNA. Literature evidence is *contradictory* across cancers; in the current LUAD cohort it is the most statistically robust protective non-pseudogene feature, but the broader cancer literature describes an oncogenic role, so the direction should be treated as a *supported hypothesis requiring external validation*.
10. **ITGB1-DT (HR=1.302, FDR=1.5e-4; Risk)** — lncRNA divergent from ITGB1. Two independent literature hits retrieved (PMID 37690573 in breast cancer; PMID 34906142 specifically in LUAD with proposed ITGB1-DT/ARNTL2 axis). This is the only selected feature with **independent literature replication** in LUAD specifically, although the literature is itself the original report and is not independent-cohort statistics.

---

## 4. Validation priorities

### Priority 1 — DKK1 as a LUAD prognostic biomarker (Biomarker / Mechanistic hypothesis)
- **Why prioritize:** DKK1 has the cleanest convergence of (i) strong finite Cox statistics in this cohort, (ii) canonical Wnt biology, (iii) prior oncology biomarker literature.
- **Current dataset evidence:** HR=1.475, FDR=3.5e-7.
- **External evidence:** DKK1 is a well-established Wnt antagonist; serum DKK1 is a known biomarker in several cancers (lung, esophageal, hepatocellular). **No independent LUAD cohort statistic was retrieved.**
- **Next step:** Validate in an independent LUAD OS cohort (e.g., TCGA-LUAD split, or a prospectively collected series); measure DKK1 by IHC and/or ELISA and test association with OS by multivariate Cox.
- **Status:** **Supported hypothesis.** Not established in LUAD specifically by independent statistics.

### Priority 2 — RGS20 / RHOF cytoskeletal-GTPase axis (Interaction / network hypothesis)
- **Why prioritize:** RGS20 has the strongest direct physical interaction evidence (≥0.8 STRING confidence with four G-protein subunits) in the entire selected cohort, and RHOF adds a parallel cytoskeletal input — a candidate protein-level module that is genuinely biologically anchored, unlike the lincRNAs.
- **Current dataset evidence:** RGS20 HR=1.352, FDR=5.8e-4; RHOF HR=1.403, FDR=4.0e-4.
- **External evidence:** STRING high-confidence interactors (GNAZ, GNB5, GNAI2, GNAQ for RGS20; ACTN1, ARHGAP1 for RHOF); Reactome Gα(i)/Gα(z) signalling. RhoF-AML literature is in a different cancer.
- **Next step:** Co-IP / proximity ligation in LUAD cell lines for RGS20–GNAZ and RHOF–ACTN1; assess whether their joint high expression adds prognostic information beyond either alone in an external cohort.
- **Status:** **Exploratory hypothesis.**

### Priority 3 — Wnt + glycosylation co-module (Interaction / network hypothesis)
- **Why prioritize:** DKK1 (Wnt) and FUT4 (glycosylation) co-occur with the retrieved KEGG batch; combined Wnt-and-glycan remodeling is a recognized axis in cancer stemness and EMT.
- **Current dataset evidence:** Both are risk-associated with FDR < 3e-4.
- **External evidence:** KEGG co-retrieval; literature on Wnt–glycan cross-talk exists but no LUAD-specific replication statistic was retrieved.
- **Next step:** Test whether DKK1-high / FUT4-high tumors share a transcriptional subtype and whether combined score improves OS prediction in an independent cohort.
- **Status:** **Exploratory hypothesis.**

### Priority 4 — Sex- and pseudogene-driven artifact audit (Confounding or composition check)
- **Why prioritize:** Roughly half the cohort is Y-linked genes, pseudogenes, or unassigned RNAs with HRs on the order of 10⁵–10²¹. If the survival model was fit without sex adjustment, these features will be **confounded with male sex** rather than with tumor biology.
- **Current dataset evidence:** 9 Y-linked genes in the top 12 risk rows; HR ≈ 5.18e21 for ≥52 rows; direction conflict in Y_RNA across 163 ledger rows; 12 unassigned Ensembl IDs.
- **External evidence:** Statistical artifact, not biology.
- **Next step:** Re-run Cox with sex, age, stage, and (if available) tumor purity as covariates; refit excluding Y-linked and pseudogene rows; verify whether the Wnt / GTPase / glycosylation signal is preserved after adjustment.
- **Status:** **Established evidence that the artifact exists; exploratory whether the remaining biology is preserved.**

### Priority 5 — CRNDE direction in LUAD (Mechanistic / Biomarker hypothesis)
- **Why prioritize:** CRNDE is the strongest protective non-pseudogene feature (HR=0.716, FDR=1.0e-4), yet the broader cancer literature calls CRNDE oncogenic. This is a real *direction conflict* worth resolving before any biomarker claim.
- **Current dataset evidence:** HR=0.716, FDR=1.0e-4.
- **External evidence:** Multiple cancer contexts describe CRNDE as pro-tumor; LUAD-specific evidence is not retrieved.
- **Next step:** Test CRNDE direction in an independent LUAD cohort and, if confirmed protective, characterize isoform usage and adjacent gene regulation.
- **Status:** **Exploratory hypothesis** with explicit conflict against the broader literature.

---

## 5. Evidence grounding (summary)

- **Direct statistical evidence from the uploaded dataset:** trusted only for genes with HRs in the biologically plausible range (~0.7–1.5) and finite P values (DKK1, TLE1, LDLRAD3, FUT4, KRT6A, RHOF, RGS20, PITX3, CRNDE, ITGB1-DT, plus the consistent lincRNAs).
- **Pathway / ontology evidence:** GO *Regulation of Wnt signaling pathway*, *Planar cell polarity pathway*, *Cell junction disassembly*; KEGG *Wnt signaling*, *Mannose-type O-glycan biosynthesis*, *Glycosphingolipid biosynthesis*. Recurrent in the pre-RAG GO/KEGG batch and independently in Reactome (Gα(i)/Gα(z) signalling).
- **Protein-interaction evidence:** RGS20 has the strongest direct STRING physical-interaction evidence (4 partners at confidence ≥0.80); RHOF and FUT4 each have moderate-confidence STRING partners; DKK1, TLE1, LDLRAD3 have weak or no STRING partners in the retrieved evidence.
- **Disease-association evidence:** DKK1 — multiple cancers (literature, not LUAD-specific cohort statistic); KRT6A — alopecia (literature, not LUAD); ITGB1-DT — breast cancer (PMID 37690573) and LUAD (PMID 34906142); RHOF — AML (PMID 34405015).
- **Expression / tissue-specific evidence (GTEx, HPA):** RGS20 is strongly brain-enriched (GTEx caudate 23.6 TPM, amygdala 14.7 TPM) — low in most peripheral tissues, which makes its tumor-tissue prognostic interpretation less parsimonious; this is a tissue-composition caveat.
- **Therapeutic evidence (ChEMBL, ClinicalTrials, OpenTargets):** no strong actionable hit in the selected cohort beyond weak hits for DKK1 and FUT4. The existence of a drug against a target is **not**, by itself, evidence of therapeutic efficacy in LUAD.
- **Independent-cohort replication:** none supplied; pathway recurrence, source coverage, and literature co-occurrence are not replication.

---

## 6. Limitations and alternative explanations

1. **Sex confounding / Y-chromosome genes.** The top-ranked "risk-associated" set is dominated by Y-linked, testis-restricted loci (RBMY1F, FAM9A, RBMY2AP, TTTY4C, TEX13A, USP9YP3, CDY10P, VENTXP7, TCP10L3). In a cohort with even modest sex imbalance, these will rank as "risk-associated" simply because male patients had different survival or follow-up. Re-fit with sex adjustment; in the worst case, exclude Y-linked rows entirely.
2. **Pseudogene and read-mapping artifacts.** A large fraction of "risk" hits are processed/unprocessed pseudogenes (HMGN2P39, ATP5PBP2, RAP1BP2, RBMY2AP, MTND1P1, ETFRF1P1, ATG4AP1, AMMECR1LP1, DNM1P49, DIMT1P1) or unassigned Ensembl IDs (`UNMAPPED_ENSEMBL_*`). These should be removed or filtered by biotype before any biological claim.
3. **Numerical instability of Cox fits.** HRs of 10⁹–10²¹ and P=FDR=0 indicate complete or near-complete separation, typically caused by a feature that is essentially zero in most samples and only nonzero in a handful. These values are not interpretable as effect sizes; treat them as QC flags.
4. **Tissue composition and tumor purity.** Without purity adjustment, the Wnt and EMT-like programs (DKK1, TLE1, KRT6A, RHOF) can reflect stromal or immune content rather than tumor-intrinsic biology. Sensitivity analyses with ESTIMATE / EPIC deconvolution scores would help.
5. **Association vs. causation and reverse causation.** All conclusions here are correlative on baseline tumor expression. Wnt-pathway activation in aggressive LUAD may be a *consequence* of tumor progression rather than its driver; orthogonal perturbation experiments (CRISPR, RNAi, small-molecule Wnt inhibitors such as PRI-724) would be needed to claim causation.

---

**Bottom line.** Once the Y-linked, pseudogene, and numerically unstable rows are set aside, the cohort reduces to a small but biologically coherent adverse-prognosis signal in **Wnt (DKK1, TLE1, LDLRAD3), glycosylation (FUT4), and Rho/G-protein signaling (RHOF, RGS20)**, plus a robust protective lncRNA candidate (CRNDE) whose direction conflicts with the broader literature and therefore requires independent validation before any biomarker claim. None of these programs has been replicated in an independent LUAD cohort within the supplied evidence pack, so all program-level conclusions are **supported hypotheses** at best, not established evidence.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=75, external claims checked=0, external mismatches=0, status=passed.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 53/100 selected items (records returned); cbioportal 51/100 selected items (records returned); chembl 16/100 selected items (records returned); civic 1/100 selected items (records returned); clinicaltrials 6/100 selected items (records returned); clinvar 30/100 selected items (records returned); ensembl 11/100 selected items (partially returned; some queries failed); europepmc 362 articles / initial full-cohort RAG 100 queries + 4 current-round queries; some queries failed; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 14/100 selected items (records returned); humanbase 56/100 selected items (partially returned; some queries failed); intact 18/100 selected items (records returned); mygene 59/100 selected items (records returned); omnipath 3/100 selected items (records returned); opentargets 55/100 selected items (records returned); pubmed 202 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 17/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 17/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 2/100 selected items (records returned); string 14/100 selected items (records returned); trrust 4/100 selected items (records returned)
